Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025…Read More

You might also be interested in reading Spotware at iFX Expo LATAM 2025: Discover cTrader Store and Powerful New IB Tools.